Which Country Is Spinraza (Nusinersen) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Spinraza (nusinersen) is an antisense oligonucleotide that modifies SMN2 pre-mRNA splicing in patients with spinal muscular atrophy, and it is not swallowed, infused into a vein, or picked up at a pharmacy counter — it is delivered as a 12 mg/5 mL intrathecal injection administered by lumbar puncture, typically under imaging guidance, in a specialised neuromuscular or paediatric neurology unit. That single fact removes Spinraza from any retail-price comparison entirely: the drug is dispensed to the hospital, not the patient, and the injection procedure itself carries its own separate cost that is never bundled into the manufacturer's list price. In Türkiye, TİTCK sets the reference price from the lowest ex-factory price found across a defined basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri) fixed at 65% of the prior year's average Central Bank euro rate rather than the live spot rate — a mechanism published on the TİTCK price list and gazetted in the Resmî Gazete. That structural mechanism, not any discount on the molecule itself, is the main reason Turkish list prices for ultra-orphan biologics sit below list prices in freely-priced markets.

Germany's AMNOG framework lets a manufacturer set a free price for the first six months after launch, after which an early-benefit assessment (Frühe Nutzenbewertung) by the IQWiG/G-BA leads to a negotiated price that is applied retroactively from month seven. Ultra-rare diseases such as spinal muscular atrophy are subject to a lighter evidentiary bar under AMNOG's orphan-drug provisions, because randomised trial data are scarce when the eligible population is small — but that provision affects the evidence required, not the currency figure. In the United Kingdom, NICE evaluates Spinraza partly through its Highly Specialised Technologies route, which applies a more generous cost-per-QALY ceiling than the standard threshold that was raised from £20,000–£30,000 to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE). A wider threshold changes what counts as "cost-effective" for a rare-disease therapy; it is not a price in itself.

The United States has no government reference-pricing mechanism equivalent to Türkiye's or Germany's for a molecule like Spinraza: manufacturers set an opening price freely, and payers negotiate confidential rebates through pharmacy benefit managers and specialty-pharmacy contracts. The RAND Corporation's 2022 international price comparison, published 1 February 2024, found gross US list prices averaged 278% of prices across 33 other high-income countries for all drugs, and 422% for brand-name originator products specifically — a structural, market-wide gap rather than a figure specific to Spinraza. Because nusinersen has no approved biosimilar and faces only indirect competition from an oral splicing modifier and a gene therapy in a different modality, there is no generic-entry price collapse of the kind seen with small-molecule drugs once patents expire.

Because Spinraza is administered exclusively in hospital, list prices published by manufacturers or ministries are a poor proxy for what any single family actually encounters: most patients are treated through national managed-entry agreements, confidential outcomes-based schemes, or expanded-access programmes that never appear in a public price list. A family evaluating "where is it cheaper" should therefore treat any published figure as a starting reference point for a specialist consultation, not a shopping price. For the underlying mechanics behind Türkiye's published reference prices specifically, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Spinraza I'm being offered genuine?

No falsified batches of Spinraza have been recorded in the WHO's medical product alert series to date. That absence of a documented alert is not, on its own, a reason to relax verification: nusinersen is a low-volume, high-value biologic administered in a small number of specialist centres worldwide, which naturally limits the informal secondary markets where falsification tends to surface for higher-volume products — it does not make the molecule immune to diversion or mishandling.

Because Spinraza must never be administered outside a hospital setting by a clinician experienced in lumbar puncture, the realistic risk for this molecule is less about street-level counterfeiting and more about cold-chain integrity during transfer between a specialist pharmacy and the treating centre, and about verifying that any vial arriving through cross-border patient-access or compassionate-use routes is genuinely sourced from Biogen's authorised supply chain rather than a grey-market intermediary.

• Scan the carton's GS1 DataMatrix and confirm it decodes correctly to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch/lot) before the vial is accepted by the treating centre.
• If the vial originates in Türkiye, verify its karekod is registered in the national İlaç Takip Sistemi (İTS) track-and-trace platform at its.saglik.gov.tr before it leaves the dispensing pharmacy.
• Request an unbroken 2–8°C temperature log for the specific shipment being administered — Spinraza must never be frozen, and any vial with visible particulates or discoloration should be rejected outright.
• Confirm the treating centre received the vial directly from an authorised specialty-pharmacy distributor rather than through a courier or private reseller, since Spinraza is not a product legitimately available through retail channels.
• Cross-check the batch number against our WHO falsified medicine alerts tracker as routine practice, even though no Spinraza-specific alert exists at present.
• Review the general verification workflow in our guide to checking that a medicine is genuine before any cross-border sourcing decision is made.
• If anything about the vial's packaging, fill volume or labelling looks inconsistent with prior shipments, contact Biogen's medical information line before the dose is prepared.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Rare-disease and orphan biologics

Related high-cost medicines